Clinical Research Directory

Inclusion Criteria: * 1\. Adults aged 19 years or older * 2\. Patients who agreed to participate in the study and signed the informed consent form * 3\. Patients whose target knee joint intended for investigational product injection meet all of the following conditions at the screening visit: * 1\) Knee joint pain due to Osteoarthritis * 2\) Kellgren-Lawrence (K-L) Grade I to III confirmed by X-ray examination * 3\) 100 mm Visual Analogue Scale (VAS) pain score of 40mm or higher during activity * 4\) Absence of significant pathological findings, such as tumors * 4\. Patients who agree to use medically acceptable methods of contraception throughout the clinical trial period Exclusion Criteria: * 1\. Patients with a known hypersensitivity or history of allergic reactions to the active substance or any components of the investigational medical device or comparator drug (e.g., porcrine-derived proteins) * 2\. Patients or their family members with autoimmune diseases * 3\. Patients with inflammatory arthritis such as rheumatoid arthritis, lupus arthritis, or psoriatic arthritis * 4\. Patients with any of the following medical history or conditions at the screening visit: * 1\) History of radiation therapy or cancer treatment within 2 years * 2\) Severe knee trauma, surgery, or injection in the knee within 6 months that makes knee evaluation difficult * 3\) Gout or calcium pyrophosphate deposition disease with onset within 6 months * 4\) Severe intra-articular effusion * 5\) Infectious disease requiring hospitalization for the administration of antibiotics * 6\) Clinically significant, medically uncontrolled disease that may interfere with the study (e.g., hepatic, cardiac, renal, oncologic, diabetic, or psyshiatric disorders) * 5\. Patients who use corticosteroids as follows at the screening visit: * 1\) intra-articular injection at the target knee within 3 months * 2\) systemic drug use within 3 months * 3\) intra-articular injection at a joint other than the target knee within 4 weeks * 4\) topical use is permitted except the target knee * 6\. Patients who have received analgesics or anti-inflammatory drugs within 48 hours prior to the screening visit * 7\. Patients who are pregnant, breastfeeding, or planning to become pregnant during the trial * 8\. Patients who have participated in other interventional studies within 30 days prior to the screening visit * 9\. Patients who are considered inappropriate for participation in this study based on the investigator's judgement